[HTML][HTML] Deficiency of platelet-derived growth factor receptor-α-positive cells in Hirschsprung's disease colon
AM O'Donnell, D Coyle, P Puri - World journal of gastroenterology, 2016 - ncbi.nlm.nih.gov
AIM: To investigate whether the expression of platelet-derived growth factor receptor-α-
positive (PDGFRα+)-cells is altered in Hirschsprung's disease (HD). METHODS: HD tissue …
positive (PDGFRα+)-cells is altered in Hirschsprung's disease (HD). METHODS: HD tissue …
Apoptotic neuron-secreted HN12 inhibits cell apoptosis in Hirschsprung's disease
C Du, H Xie, R Zang, Z Shen, H Li, P Chen… - International Journal …, 2016 - Taylor & Francis
Perturbation in apoptosis can lead to Hirschsprung's disease (HSCR), which is a genetic
disorder of neural crest development. It is believed that long noncoding RNAs (lncRNAs) …
disorder of neural crest development. It is believed that long noncoding RNAs (lncRNAs) …
GFRA4 improves the neurogenic potential of enteric neural crest stem cells via hedgehog pathway
F Zhang, M Cui, L Zhang, B Ma, F Guo, G Wang - Pediatric Research, 2024 - nature.com
Background Hirschsprung disease (HSCR) is a congenital intestinal disease characterised
by functional obstruction of the colon. Herein, we investigated the role and mechanism of the …
by functional obstruction of the colon. Herein, we investigated the role and mechanism of the …
Routine botulinum toxin injection one month after a Swenson pull-through does not change the incidence of Hirschsprung associated enterocolitis
H Ahmad, RM Rentea, ME Knaus, JG Wilbur… - Journal of Pediatric …, 2022 - Elsevier
Abstract Purpose Patients with Hirschsprung disease (HD) are at risk of Hirschsprung
associated enterocolitis (HAEC) following pull-through. The purpose of this study was to …
associated enterocolitis (HAEC) following pull-through. The purpose of this study was to …
Substituted pyrazolo [1, 5-a] pyridine compounds as RET kinase inhibitors
SW Andrews, S Aronow, JF Blake… - US Patent …, 2018 - Google Patents
2018-10-05 Assigned to ARRAY BIOPHARMA INC. reassignment ARRAY BIOPHARMA
INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS) …
INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS) …
Substituted pyrazolo [1, 5-A] pyridine compounds as RET kinase inhibitors
SW Andrews, S Aronow, JF Blake… - US Patent …, 2019 - Google Patents
2018-10-05 Assigned to ARRAY BIOPHARMA INC. reassignment ARRAY BIOPHARMA
INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS) …
INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS) …
IGF 2‐derived miR‐483‐3p associated with Hirschsprung's disease by targeting FHL 1
Z Zhi, H Zhu, X Lv, C Lu, Y Li, F Wu… - Journal of Cellular …, 2018 - Wiley Online Library
HSCR (Hirschsprung's disease) is a serious congenital defect, and the aetiology of it
remains unclear. Many studies have highlighted the significant roles of intronic mi RNA s …
remains unclear. Many studies have highlighted the significant roles of intronic mi RNA s …
[HTML][HTML] Congenital anomalies of the tubular gastrointestinal tract
K Ludwig, D De Bartolo, A Salerno, G Ingravallo… - Pathologica, 2022 - ncbi.nlm.nih.gov
Congenital anomalies of the tubular gastrointestinal tract - PMC Back to Top Skip to main
content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main …
content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main …
Are we underdiagnosing Hirschsprung disease?
RP Kapur, L Ambartsumyan… - Pediatric and …, 2020 - journals.sagepub.com
Hirschsprung disease (HSCR) is conventionally defined as aganglionosis of the distal
rectum and a variable length of proximal contiguous bowel with a transition zone of …
rectum and a variable length of proximal contiguous bowel with a transition zone of …
Substituted pyrazolo [1, 5-A] pyridine compounds as RET kinase inhibitors
SW Andrews, S Aronow, JF Blake… - US Patent …, 2019 - Google Patents
2018-12-03 Assigned to ARRAY BIOPHARMA INC. reassignment ARRAY BIOPHARMA
INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS) …
INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS) …